ReviewJournal of neuro-oncology2026
Update of NK cell therapy in pediatric brain tumors.
Review in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain tumors in children are the leading cause of cancer-related mortality. Despite advances in various treatment modalities, overall survival has remained poor for these malignancies. Immunotherapy has garnered enthusiasm as a new therapeutic paradigm for these tumors, yet the constraints of the blood-brain barrier (BBB), low mutational burden and the immunosuppressive microenvironment have undermined clinical efficacy. PURPOSE: The primary objective of this article is to review NK cell pathophysiology and the preclinical studies that have led to its translation into clinical trials for pediatric brain tumors (PBTs). An overview of strategies to reprogram NK cells, enhance their persistence and homing to tumor sites, and mitigate the tumor microenvironment (TME) will be presented.
resultsUse of NK cell therapy is now gaining momentum in PBTs due to its inherent tumor-killing mechanisms, which preclude the need for prior sensitization and MHC-dependent antigen recognition. Off-the-shelf sources of NK cells are often favored due to their lower cost, shorter manufacturing time, and quicker access to patients than autologous cells. Improved methods of ex vivo expansion and innovative multiplexed engineering approaches enable delivery of more efficient NK cells, empowered with robust tumor-specific cytotoxicity, longer in vivo persistence and resistance to the impediments of the TME.
conclusionThe development of newer generations of engineered NK cells now ushers in an era of therapeutic optimism for the treatment of brain tumors. Efforts are ongoing to deliver safe and efficacious clinical trials using these novel therapeutics.
Indexed as
Identifiers
41678060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.